1017294-05-1

Basic information

• Product Name: (R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER
• Synonyms: (R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER;METHYL N-ACETYL-3-(2,5-DIFLUOROPHENYL)-D-ALANINATE
• CAS NO: 1017294-05-1
• Molecular Formula: C₁₂H₁₃F₂NO₃
• Molecular Weight: 257.23
• Mol File: 1017294-05-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER(1017294-05-1)
• EPA Substance Registry System: (R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER(1017294-05-1)

Safety Data

• Hazardous Substances Data: 1017294-05-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER is used as an active pharmaceutical ingredient for its pain-relieving and anti-inflammatory properties. It is particularly effective in treating conditions such as arthritis, menstrual cramps, and other forms of acute and chronic pain.
Used in Pain Management:
(R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER is used as a pain management agent to alleviate discomfort and reduce inflammation associated with various medical conditions.
Used in Inflammation Treatment:
(R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER is used as an anti-inflammatory agent to reduce swelling and inflammation in the body, which can be beneficial for patients suffering from conditions like arthritis.
Used in Oral Administration:
(R)-2-ACETYLAMINO-3-(2,5-DIFLUORO-PHENYL)-PROPIONIC ACID METHYL ESTER is used in oral pharmaceutical formulations, such as tablets and capsules, to provide convenient and effective treatment options for patients.

Upstream product

• 1346680-23-6 (Z)-methyl 2-acetamido-3-(2,5-difluorophenyl)acrylate 
• 959246-87-8 C₁₂H₁₁F₂NO₃ 

Downstream Products

• 923564-34-5 2-dibenzylamino-3-(2,5-difluoro-phenyl)-propan-1-ol 
• 1017294-02-8 (R)-2-dibenzylamino-3-(2,5-difluoro-phenyl)-propionaldehyde 
• 1017294-00-6 N-tert-butyl-2-[3-dibenzylamino-4-(2,5-difluoro-phenyl)-2-hydroxy-butyl]-6-trifluoromethyl-nicotinamide 

Relevant articles and documents

P-Stereogenic N-Phosphine-Phosphite Ligands for the Rh-Catalyzed Hydrogenation of Olefins

We have identified a successful family of simple P-stereogenic N-phosphine-phosphite ligands for the Rh-catalyzed asymmetric hydrogenation of olefins. These catalysts show excellent enantiocontrol for α-dehydroamino acid derivatives and α-enamides (ee's u

Chiral rhodium complexes derived from electron-rich phosphine-phosphites as asymmetric hydrogenation catalysts

Two new chiral cationic rhodium(I) complexes derived from electron-rich dicyclohexylphosphine-phosphite ligands were prepared from enantiopure Sharpless epoxy ethers. The best-performing catalyst system, which bears a less bulky methyl ether moiety, exhibited remarkably high enantioselectivity (up to 99% ee) and reactivity (up to >2500 TON) in asymmetric hydrogenation reactions of various functionalized alkenes (α-(acylamino)acrylates, itaconic acid derivatives, α-substituted enol esters and α-arylenamides). Our synthetic methodology has been successfully applied to the enantioselective synthesis of the antiepileptic drug (R)-lacosamide (Vimpat).

Enantioselective access to chiral drugs by using asymmetric hydrogenation catalyzed by Rh(P-OP) complexes

P-OP art: Rhodium complexes of P-OP ligands serve as highly efficient and enantioselective catalysts in asymmetric hydrogenation leading to various valuable pharmaceutical building blocks and several direct precursors of chiral drugs such as LY2497282, la

Development of a pratical synthisis of DPP IV inhibitor LY2497282

A new synthetic route to LY2497282 (1), a potent and selective DPP IV inhibitor for the potential treatment of diabetes, suitable for the preparation of multikilogram quantities is described. The key step involved a stereoselective addition of the dianion of nicotinamide 8 to iV-dibenzyl-protected α-amino aldehyde 12, which was derived from iV-acetyl-protected amino ester 14 without epimerization. The desired Felkin-Anh nonchelation controlled anti-amino alcohol 11 was isolated with >99% HPLC area and > 99% ee by crystallization. After removing the dibenzyl protecting group under transfer hydrogenation conditions, LY2497282 (1) was finally obtained in 39% overall yield with a six-step longest linear sequence starting from N-acetyl-protected amino ester 14.